Do you need a Texas-based partner for your CPRIT grant?
Interested in our services?

Why Cancer Insight

Founded by cancer immunotherapy pioneer Dr. George Peoples, the founder of the Cancer Vaccine Development Program, and based on a history of scientific innovation and a passion for exploring new strategies to achieve success, Cancer Insight’s mission is to eradicate cancer through the discovery of effective and safe cancer immunotherapy treatment. Cancer Insight offers exceptional CRO services [What Can We Do For You] within an academic ecosystem built to provide value and insight beyond expectation.

Our Unique Approach

At Cancer Insight, we understand the intricacies of developing and executing research initiatives. We approach every project from a scientific and academic perspective as well as a strategic business perspective to help our clients develop sound research models to achieve effective results with highly targeted endpoints based on needs and expectations.  Our academic ecosystem encourages a collaborative environment with our clients.  We share our progress to prompt conversation, building in an iterative process to turn ideas into solutions with each project. We have intentionally brought together a diverse set of capabilities in academia and business management expertise to deliver CRO services that go beyond expectation.

We have a specific focus on finding innovative solutions in the area of cancer immunotherapy.  We intend to develop immunotherapy treatments that can target large numbers of cancers and cancer patients.  We intend to utilize simplistic approaches that can be exported to the community setting.

We deliver:

  • An understanding of and commitment to your investment
  • A strong network of research partners
  • A collaborative approach to help you validate and improve your plan
  • An effective and efficiently managed study
  • A high value proposition
  • A history of success

Our History

For the past 20 years, our scientific team has been designing, developing, and testing cancer vaccines for their ability to specifically stimulate the host immune system to recognize and kill cancer cells.

Currently, five of our vaccines, E75, GP2, E39, E39’, and AE37 have been licensed out to industry partners. The research that propelled these vaccines to this stage of development was performed by the Cancer Vaccine Development Program founded and directed since its inception in 2000 by COL George E Peoples, MD, FACS.

Dr. Peoples retired from the military in 2014 and formed Cancer Insight, a commercial partner to the academic CVDP.

Our team’s experience includes:

  • 15 years of therapeutic product development
  • 15 years of experience in designing and conducting clinical trials
  • 5 commercial products in late stage development
  • 14 patent families (>100 patents issued worldwide)
  • Management of 7 INDs from creation to phase 3
  • Enrollment of over 1500 patients
  • 225 national presentations
  • 320 peer-reviewed publications
  • 143 manuscripts
  • 169 abstracts
  • 11 book chapters
  • Currently conducting phase I and II trials ranging from 30-300 patients at 1-33 sites

Our Proof

We have decades of experience in developing and executing research projects, with over 169 abstracts and 143 manuscripts published, and management of 7 INDs from creation to phase 3.